IN BRIEF: Solvonis Therapeutics hails US patent from PTSD programme

Solvonis Therapeutics PLC - London-based biopharmaceutical company, focused on central nervous ...

Alliance News 8 April, 2026 | 1:31PM
Email Form Facebook Twitter LinkedIn RSS

Solvonis Therapeutics PLC - London-based biopharmaceutical company, focused on central nervous system disorders - Celebrates second US patent by United States Patent & Trademark Office, covering a further monoamine modulator compound series arising from its proprietary post-traumatic stress disorder discovery programme. The patent, U.S. Patent No. 12,595,269, was issued on Tuesday. On March 31, the company had announced the first such patent, U.S. Patent No. 12,590,077.

Solvonis Chief Scientific Officer David Nutt says: "This second patent reflects the breadth of our monoamine modulation research and the scientific strategy behind it. By exploring multiple chemically distinct series acting across serotonin, dopamine and noradrenaline transporter systems, we increase the probability of identifying differentiated compounds with attractive translational and therapeutic profiles."

Current stock price: 0.27 pence each, flat on Wednesday afternoon in London

12-month change: up 59%

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2026 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Solvonis Therapeutics PLC Ordinary Share 0.27 GBX -0.22 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures